Yuanjun Wu Yong Wu Yong Yang Baochan Chen Jianqun Li Ganping Guo Fu Xiong
10.3389/fimmu.2021.698541
Front Immunol
2021 Dec 22;12:698541.
acute intravascular hemolysis cefotaxime drug-induced immune hemolytic anemia (diiha) hemolytic disease of newborn (hdn) non-immunologic protein adsorption (nipa) sulbactam
CC BY
https://pubmed.ncbi.nlm.nih.gov/35003054/
ABO Blood-Group System / immunology Anemia, Hemolytic / chemically induced Blood Group Incompatibility / complications Cefotaxime / adverse effects Erythroblastosis, Fetal / etiology Hemolysis Immunoglobulin G / immunology Isoantibodies / immunology Sulbactam / adverse effects
ABO Blood-Group System / immunology Anemia, Hemolytic / chemically induced Blood Group Incompatibility / complications Cefotaxime / adverse effects Erythroblastosis, Fetal / etiology Hemolysis Immunoglobulin G / immunology Isoantibodies / immunology Sulbactam / adverse effects Case Reports Research Support, Non-U.S. Gov't Acute Disease Adsorption Anemia, Hemolytic / blood Antigen-Antibody Reactions Blood Group Incompatibility / blood Cefotaxime / administration & dosage Complement Activation Coombs Test Erythroblastosis, Fetal / blood Erythrocyte Membrane / chemistry Erythrocyte Membrane / immunology Fatal Outcome Female Humans Infant, Newborn Male Maternal-Fetal Exchange Pregnancy Sulbactam / administration & dosage Young Adult ABO Blood-Group System Immunoglobulin G Isoantibodies Cefotaxime Sulbactam
PMC8727536
35003054
Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption
2021